The triage model flagged the excursion as non-impacting. The confidence score was high. The reviewer accepted the recommendation and signed the closure. Total elapsed time: under four minutes.

Eighteen months later, an investigator pulls the file. The reviewer is at another company. The model has been retrained twice. The deviation report shows the closure, the signature, the timestamp, and the AI recommendation. It does not show what evidence the reviewer reviewed beyond what the model surfaced. Whether she questioned the recommendation. Why a four-minute review was sufficient for a decision that, in retrospect, raises questions.

The investigator asks who authorized reliance on the AI-assisted conclusion, against what acceptance criteria, and where the documented review lives.

There is no good answer. Not because the reviewer was careless. Because the system was built to document execution, not the reasoning behind acceptance.

This pattern is not hypothetical and it is not rare. AI is being introduced into deviation triage, process monitoring, contamination prediction, predictive maintenance, trend analysis, CAPA recommendation, and manufacturing optimization. Each application produces the same structural result. The systems document what happened. They do not document how an experienced reviewer reasoned through whether to accept what the model recommended.

That gap is where the next phase of regulatory exposure is accumulating.

The question has narrowed

The FDA does not inspect AI as a category. It inspects product quality, patient safety, data integrity, change control, deviation management, validation, release authorization, and GMP accountability. When AI influences any of those activities, the question becomes specific: who authorized reliance on the AI-assisted output, under what procedure, against what acceptance criteria, and with what documented review?

For most organizations, that answer is harder to reconstruct than it should be. The batch record shows the process steps, the analytical results, the deviation closure, the disposition, and the electronic signatures. It does not show what evidence was reviewed, what alternatives were considered, what risks were accepted, what the AI recommended, what the human reviewer accepted or rejected, or why the final conclusion was approved.

That missing layer is where the exposure accumulates.

AI multiplies the decisions that go undocumented

Every AI-assisted recommendation creates a decision point inside the GMP environment. A model classifies a deviation as minor. A monitoring system flags an excursion as non-impacting. An AI workflow recommends a batch disposition. A language model drafts a CAPA rationale.

Each output leaves the same questions behind. Who reviewed it. What standard was applied. What was accepted. What was rejected. Where the reasoning was documented.

Before AI, those questions had a person at the center — a reviewer who had worked through the file, weighed the evidence, and reached a conclusion. The reasoning still often went undocumented, but at least there was a single human decision-maker accountable for it. AI fragments that. The reasoning is now distributed between the model's logic, the reviewer's interpretation of the model's output, and the procedural framework that governs whether the reviewer is permitted to defer to the model in the first place.

Explainability solves a different problem

Vendors emphasize explainability as the answer. It is not, or at least not the whole answer.

A model can explain its variables, its confidence interval, its statistical pathway. None of that answers the question an investigator will ask. Explainability describes how the system reached a recommendation. Accountability describes how the organization decided to rely on it. In a GMP environment, the second question is the consequential one.

A reviewer can read the model's explanation, find it convincing, and accept the recommendation. The acceptance is the regulated act. The reasoning behind the acceptance — what made the explanation convincing, what alternatives were considered, what risks were judged acceptable, what made the reviewer's expertise applicable to this particular case — is the part that almost never gets captured.

That part is what an investigator is asking for.

The reconstruction problem

Most organizations assume their systems already contain the answer. They usually do not.

The reasoning behind GMP decisions tends to live in conversations, emails, undocumented discussions, fragmented systems, and individual expertise. The logic is distributed across people and platforms. When an inspection or audit or product event surfaces the question months or years later, the people who made the decision may have moved on, the systems they used may have been updated, and the institutional memory of why the decision was made the way it was may have evaporated.

Reconstruction in that environment is expensive, slow, and often incomplete. It is also the moment at which most organizations discover that their compliance posture depended on the memory of specific individuals more than they realized.

The exposure is not only regulatory. Warning letter remediation, inspection preparation, delayed releases, legal review, and external consulting can all become significant burdens when the authorization path for a specific decision cannot be clearly demonstrated.

What the next phase will reward

The first phase of AI adoption in regulated manufacturing was about capability — whether the models worked, whether they could be validated, whether they could integrate with existing systems. That phase is not over, but it is no longer the differentiating one.

The next phase will be defined by governance. Not whether AI accelerates GMP operations — that question is settled — but whether the organization can still demonstrate, after the fact, how a critical GMP conclusion was made, reviewed, and authorized.

The companies that get this right will not simply have the most advanced models. They will have built three things their competitors have not. A documented standard against which a reviewer's acceptance of an AI recommendation is weighed, so two reviewers at two sites looking at the same model output reach the same conclusion. A method for letting a new reviewer pick up where a senior reviewer left off without re-deriving twenty years of judgment about when AI recommendations are reliable and when they are not. A documented basis for each consequential decision, in a form that lets a different qualified person reach the same conclusion from the same evidence eighteen months later.

Those three capabilities are not currently part of most organizations' digital quality stack. They are not what the QMS is built for. They are not what the eBR captures. They are not what the AI vendor's explainability layer provides.

They are the work that has to be added.

AI will accelerate GMP operations. That much is clear. The harder question, and the one that will shape regulatory exposure for the next decade, is whether the industry will build the systems that preserve accountable reasoning at the same pace.